A clinical trial of the combination of sabatolimab (anti-TIM-3 antibody) and spartalizumab (anti-PD-1 antibody) has also been carried out and showed some signs of anti-tumor immunity (151). This evidence concerns the gene PDCD1 and neoplasm.